Finoriq research workspace
20/20 Biolabs, Inc. (AIDX) Company Overview
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early. Review AIDX filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
- Company
- 20/20 Biolabs, Inc. (AIDX)
- Ticker
- AIDX
- Market Cap
- $6.4M
- Latest Price
- $0.5188
- Industry
- Precision Instruments
20/20 Biolabs, Inc. (AIDX) Current Valuation Metrics
Static valuation preview for 20/20 Biolabs, Inc. (AIDX). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 3.54x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -51.7% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -26.5% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 2.83x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.